AMAG Pharmaceuticals, Inc. announced the appointment of Laura Williams, M.D., M.P.H., as senior vice president of clinical development effective immediately. She will report to Julie Krop, M.D., chief medical officer and senior vice president of clinical development and regulatory affairs at AMAG. Dr. Williams has more than 20 years of pharmaceutical experience, spanning all phases of drug development and across numerous therapeutic areas, including her more recent work with compounds and products aimed at solving unmet medical needs in women’s health. In her role at AMAG, Dr. Williams is responsible for the overall strategy and execution of clinical development activities, including study design and data interpretation. She will work with the regulatory, quality, clinical and technical operations teams to support new drug development, as well as regulatory filings and approvals. Prior to joining AMAG, she served as vice president of clinical development at Myovant Sciences, where she oversaw clinical development for an infertility treatment and co-led business development activities to expand the women’s health pipeline.